XW033MAIntroduction of Emapalumab-lzsg Anti-IFNy Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 10

  • Billable / Specific Code
ICD-10-PCS XW033MA
CMS Source: FY 2026 ICD-10-PCS dataset. Effective Oct 1, 2025 – Sep 30, 2026.FacebookXLinkedInPrint

XW033MA is a billable ICD-10-PCS procedure code for Introduction of Emapalumab-lzsg Anti-IFNy Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 10. It is valid on HIPAA claims for fiscal year 2026 (October 1, 2025 through September 30, 2026). The root operation Introduction involves putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products.

Code Identity

ICD-10-PCS Code
XW033MA
Billable Status
Yes — Valid for Submission
Code Describes
Introduction of Emapalumab-lzsg Anti-IFNy Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 10
Parent Code
Short Description
Introduce Emapalumab-lzsg in Periph Vein, Perc, New Tech 10

PCS Table Breakdown

Each ICD-10-PCS code is built from seven characters, each an axis of the procedure. Hover or tap the icons for the official CMS definitions.

PositionDesignationValueMeaning
1SectionXNew Technology
2Body SystemWAnatomical Regions
3Operation0Introduction
4BodyPart3Peripheral Vein
5Approach3Percutaneous
6Device/Substance/TechnologyMEmapalumab-lzsg Anti-IFNy Monoclonal Antibody
7QualifierANew Technology Group 10

Code History

Replaces previously assigned code(s):
  • 3E033GR — Introduce Oth Rx Moncln Ab in Periph Vein, Perc

Similar Procedure Codes

Questions About XW033MA

Is XW033MA a billable code?

Yes. XW033MA is a complete seven-character ICD-10-PCS code, specific enough to report Introduction of Emapalumab-lzsg Anti-IFNy Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 10 on inpatient claims from October 1, 2025 through September 30, 2026.

What do the characters in XW033MA mean?

XW033MA breaks down character by character: the 1st character X is the Section (New Technology); the 2nd character W is the Body System (Anatomical Regions); the 3rd character 0 is the Operation (Introduction); the 4th character 3 is the BodyPart (Peripheral Vein); the 5th character 3 is the Approach (Percutaneous); the 6th character M is the Device/Substance/Technology (Emapalumab-lzsg Anti-IFNy Monoclonal Antibody); the 7th character A is the Qualifier (New Technology Group 10).